日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

阿米万单抗联合化疗治疗EGFR 20号外显子插入突变的非小细胞肺癌:PAPILLON III期研究中治疗交叉及其他终点的影响

Sanborn, Rachel E; Zhou, Caicun; Tang, Ke-Jing; Cho, Byoung Chul; Cheng, Susanna; Popat, Sanjay; Ono, Akira; Lu, Shun; Majem, Margarita; Aguilar, Andres; Del Rosario Garcia Campelo, Maria; Hayashi, Hidetoshi; Lee, Kang-Yun; Lee, Se-Hoon; Delmonte, Angelo; Alatorre-Alexander, Jorge; Richardson, Gary; Santos, Victor; Dooms, Christophe; Sabari, Joshua K; Shu, Catherine A; Girard, Nicolas; Mansfield, Aaron S; Park, Keunchil; Xia, Yichuan; Bhattacharya, Archan; Buyukkaramikli, Nasuh; Perualila, Nolen; Diels, Joris; Acharya, Sandip; Chandler, Conor; Proskorovsky, Irina; Dearden, Lindsay; Wortman-Vayn, Honeylet; Mahadevia, Parthiv J; Knoblauch, Roland E; Agrawal, Trishala; Baig, Mahadi; Felip, Enriqueta

An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease

一项关于阿伐葡萄糖苷酶α与西帕葡萄糖苷酶α联合米格司他治疗晚发型庞贝病患者的间接治疗比较研究

Roberts, Mark E; Proskorovsky, Irina; Guyot, Patricia; Shukla, Pragya; Thibault, Nathan; Hamed, Alaa; Pulikottil-Jacob, Ruth; O'Callaghan, Lasair; Pollissard, Laurence

Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials

阿伐葡萄糖苷酶α对初治晚发型庞贝病患者用力肺活量占预计值的百分比的影响:一项临床试验汇总分析

Mozaffar, Tahseen; Riou França, Lionel; Msihid, Jérôme; Shukla, Pragya; Proskorovsky, Irina; Zhou, Tianyue; Periquet, Magali; An Haack, Kristina; Pollissard, Laurence; Straub, Volker

Modeling severe uncontrolled asthma: Transitioning away from health states

严重失控哮喘建模:从健康状态过渡

Lanitis, Tereza; Khan, Asif H; Proskorovsky, Irina; Houisse, Ivan; Kuznik, Andreas; Kamat, Siddhesh; Franco-Villalobos, Conrado; Joulain, Florence

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States

在美国,Lisocabtagene Maraleucel 与 Axicabtagene Ciloleucel 和 Tisagenlecleucel 在复发或难治性大 B 细胞淋巴瘤三线或后续治疗中的成本效益分析

Parker, Christopher; Liu, Fei Fei; Deger, Kristen A; Franco-Villalobos, Conrado; Proskorovsky, Irina; Keating, Scott J; Sorensen, Sonja

Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study

帕金森病新治疗策略的长期健康和经济影响建模:一项个体患者模拟研究

Chandler, Conor; Folse, Henri; Gal, Peter; Chavan, Ameya; Proskorovsky, Irina; Franco-Villalobos, Conrado; Yang, Yunyang; Ward, Alex

Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

针对以下问题的致编辑信的回复:Inotuzumab Ozogamicin 与 Blinatumomab 治疗复发或难治性急性淋巴细胞白血病的间接治疗比较

Proskorovsky, Irina; Vandendries, Erik; Pagé, Véronique; Cappelleri, Joseph C; Stelljes, Matthias

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

伊诺妥珠单抗与布林妥莫单抗治疗复发或难治性急性淋巴细胞白血病的间接治疗比较

Proskorovsky, Irina; Su, Yun; Fahrbach, Kyle; Vandendries, Erik; Pagé, Véronique; Onyekwere, Uchenna; Wang, Yunyang; Cappelleri, Joseph C; Stelljes, Matthias

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

接受阿维鲁单抗治疗的转移性默克尔细胞癌患者的生存分析

Lanitis, Tereza; Proskorovsky, Irina; Ambavane, Apoorva; Hunger, Matthias; Zheng, Ying; Bharmal, Murtuza; Phatak, Hemant

Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial

EMPA-REG OUTCOME试验中,对患有2型糖尿病和已确诊心血管疾病的患者进行恩格列净治疗的成本效益分析

Kansal, A; Reifsnider, O S; Proskorovsky, I; Zheng, Y; Pfarr, E; George, J T; Kandaswamy, P; Ruffolo, A